[1] |
LIU Z Y, ZHANG Y L, ZHU Y C, et al. Prognosis of intravascular large B cell lymphoma (IVLBCL): analysis of 182 patients from global case series[J]. Cancer Manag Res, 2020, 12: 10531-10540.
doi: 10.2147/CMAR.S267825
pmid: 33122951
|
[2] |
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours (5th ed)[M]. Lyon (France): International Agency for Research on Cancer, 2024.
|
[3] |
HANS C P, WEISENBURGER D D, GREINER T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1): 275-282.
doi: 10.1182/blood-2003-05-1545
pmid: 14504078
|
[4] |
WAWIRE J, SAYED S, MOLOO Z, et al. Diffuse large B-cell lymphoma in Kenya: MYC, BCL2, and the cell of origin[J]. J Glob Oncol, 2019, 5: 1-8.
doi: 10.1200/JGO.18.00203
pmid: 31045473
|
[5] |
CAMPUZANO-ZULUAGA G, CIOFFI-LAVINA M, LOSSOS I S, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases[J]. Leuk Lymphoma, 2013, 54(11): 2405-2411.
|
[6] |
SWERDLOW S H, CAMPO E, HARRIS N L, et al. World Health Organization classification of tumors of haematopoietic and lymphoid tissues[M]. Lyon: International Agency for Research on Cancer, 2008.
|
[7] |
MURASE T, YAMAGUCHI M, SUZUKI R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5[J]. Blood, 2007, 109(2): 478-485.
doi: 10.1182/blood-2006-01-021253
pmid: 16985183
|
[8] |
中华医学会血液学分会淋巴细胞疾病学组, 中国临床肿瘤学会CSCO淋巴瘤专家委员会. 血管内大B细胞淋巴瘤诊治中国专家共识(2023年版)[J]. 中华血液学杂志, 2023, 44(3): 177-181.
|
|
Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association; Lymphoma Expert Committee of Chinese Society of Clinical Oncology CSCO. Chinese expert consensus on the diagnosis and management of intravascular large B cell lymphoma (2023)[J]. Chin J Hematol, 2023, 44(3): 177-181.
|
[9] |
MATSUE K, ABE Y, NARITA K, et al. Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20years[J]. Br J Haematol, 2019, 187(3): 328-336.
|
[10] |
KIRIAKOPOULOS A, LINOS D. Intravascular B-large cell lymphoma: an unexpected diagnosis of an incidental adrenal mass[J]. J Surg Case Rep, 2019, 2019(2): rjz048.
|
[11] |
FUKUSHIMA A, OKADA Y, TANIKAWA T, et al. Primary bilateral adrenal intravascular large B-cell lymphoma associated with adrenal failure[J]. Intern Med, 2003, 42(7): 609-614.
|
[12] |
YU Y, GOVINDARAJAN R. Intravascular large B-cell lymphoma presenting as an isolated cauda equina-conus medullaris syndrome-a case report[J]. J Spinal Cord Med, 2020, 43(4): 556-559.
|
[13] |
TAKAHASHI Y, IIDA K, HINO Y, et al. Silent intravascular lymphoma initially manifesting as a unilateral adrenal incidentaloma[J]. Case Rep Med, 2012, 2012: 849285.
|
[14] |
LI W, LIN W, MA C, et al. A case of intravascular large B-cell lymphoma in the left adrenal and another tumor in the right adrenal detected by (18)F-FDG PET/CT[J]. Hell J Nucl Med, 2016, 19(1): 57-59.
doi: 10.1967/s002449910342
pmid: 26929945
|
[15] |
CUI J, LIU Q, CHENG Y X, et al. An intravascular large B-cell lymphoma with a t(3;14)(q27;q32) translocation[J]. J Clin Pathol, 2014, 67(3): 279-281.
doi: 10.1136/jclinpath-2013-201980
pmid: 24357441
|
[16] |
SRIVATSA S, SHARMA J, LOGANI S. Intravascular lymphoma: an unusual diagnostic outcome of an incidentally detected adrenal mass[J]. Endocr Pract, 2008, 14(7): 884-888.
doi: 10.4158/EP.14.7.884
pmid: 18996818
|
[17] |
VENIZELOS I, TAMIOLAKIS D, PETRAKIS G. High grade primary adrenal intravascular large B-cell lymphoma manifesting as Addison disease[J]. Rev Esp Enferm Dig, 2007, 99(8): 471-474.
pmid: 18020866
|
[18] |
ASKARIAN F, XU D S. Adrenal enlargement and insufficiency: a common presentation of intravascular large B-cell lymphoma[J]. Am J Hematol, 2006, 81(6): 411-413.
pmid: 16680734
|
[19] |
COLAVOLPE C, EBBO M, TROUSSE D, et al. FDG-PET/CT is a pivotal imaging modality to diagnose rare intravascular large B-cell lymphoma: case report and review of literature[J]. Hematol Oncol, 2015, 33(2): 99-109.
doi: 10.1002/hon.2140
pmid: 24850057
|
[20] |
SCHRADER A M R, JANSEN P M, WILLEMZE R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma[J]. Blood, 2018, 131(18): 2086-2089.
|
[21] |
BOONSAKAN P, IAMSUMANG W, CHANTRATHAMMACHART P, et al. Prognostic value of concurrent expression of C-MYC and BCL2 in intravascular large B-cell lymphoma: a 10-year retrospective study[J]. Biomed Res Int, 2020, 2020: 1350820.
|
[22] |
YEGAPPAN S, COUPLAND R, ARBER D A, et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma[J]. Mod Pathol, 2001, 14(11): 1147-1156.
|
[23] |
YAMAGUCHI M, SETO M, OKAMOTO M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients[J]. Blood, 2002, 99(3): 815-821.
|
[24] |
GUPTA G K, JAFFE E S, PITTALUGA S. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features[J]. Histopathology, 2019, 75(2): 282-286.
doi: 10.1111/his.13870
pmid: 30938862
|
[25] |
SUEHARA Y, SAKATA-YANAGIMOTO M, HATTORI K, et al. Liquid biopsy for the identification of intravascular large B-cell lymphoma[J]. Haematologica, 2018, 103(6): e241-e244.
|
[26] |
SHIMADA K, YOSHIDA K, SUZUKI Y, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma[J]. Blood, 2021, 137(11): 1491-1502.
doi: 10.1182/blood.2020007245
pmid: 33512416
|
[27] |
WILSON W H, YOUNG R M, SCHMITZ R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J]. Nat Med, 2015, 21(8): 922-926.
doi: 10.1038/nm.3884
pmid: 26193343
|
[28] |
XIE J L, SHEN X, SHI Q, et al. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma[J]. Hematol Oncol, 2022, 40(5): 885-893.
|
[29] |
JIANG S Y, QIN Y, GUI L, et al. Genomic alterations and MYD88MUT variant mapping in patients with diffuse large B-cell lymphoma and response to ibrutinib[J]. Target Oncol, 2020, 15(2): 221-230.
|
[30] |
ZENZ T, KREUZ M, FUGE, et al. TP53 mutation and survival in aggressive B cell lymphoma[J]. Int J Cancer, 2017, 141(7): 1381-1388.
doi: 10.1002/ijc.30838
pmid: 28614910
|
[31] |
JACOBS G, HELLMIG S, HUSE K, et al. Polymorphisms in the 3’-untranslated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma[J]. Haematologica, 2011, 96(7): 987-995.
|
[32] |
CARRERAS J, IKOMA H, KIKUTI Y Y, et al. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement[J]. Virchows Arch, 2024, 484(4): 657-676.
|
[33] |
DE MIRANDA N F, PENG R J, GEORGIOU K, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas[J]. J Exp Med, 2013, 210(9): 1729-1742.
|
[34] |
ZHANG Y, JIA C W, WANG W, et al. The interim analysis from a prospective single-center phase 2 study of zanubrutinib plus R-CHOP in treat-Naïve intravascular large B cell lymphoma[J]. Blood, 2021, 138(Supplement 1): 3563.
|
[35] |
RAJYAGURU D J, BHASKAR C, BORGERT A J, et al. Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database[J]. Leuk Lymphoma, 2017, 58(9): 1-9.
|